



Post Authorisation Assessments

Vanguard CPV-L

Vm 42058/5180

14 January 2025	Change in legal entity of MA holder for Northern Ireland only from Zoetis UK Limited, 1st Floor, Birchwood Building, Springfield Drive, Leatherhead, Surrey, KT22 7LP to Zoetis Belgium S.A., 2nd Floor, Building 10, Cherrywood Business Park, Loughlinstown, Dublin 18, D18 T3Y1 Ireland.
14 June 2024	a. The addition of acceptable countries of origin as source for the porcine pancreas used to make the porcine trypsin powder. b. The removal of the countries of origin for the lactose used in the production process of porcine trypsin. c. To make some editorial changes in the TSE risk assessment.
25 March 2024	Change in the source of a starting material used in the manufacturing process of the active substance.
18 November 2022	Introduction of in vitro antigen capture ELISA potency test. Use of antigen capture ELISA to quantify antigen.
01 May 2020	Change in the address of the marketing authorisation holder from Zoetis UK Limited, 5th Floor, 6 St. Andrew Street, London, EC4A 3AE to Zoetis UK Limited, 1st Floor, Birchwood Building, Springfield Drive, Leatherhead, Surrey, KT22 7LP.
19 October 2018	Change in the specification parameters and/or limits of the finished product.
09 November 2016	Change in the composition (excipients) of the finished product.
19 February 2014	Transfer of MA from Pfizer Ltd to Zoetis UK Limited and change of distributor. Change of name of the active substance manufacturer and change of name of the finished product manufacturer responsible for batch release.
16 December 2010	Renewal
18 November 2010	Removal of a test.
07 July 2010	Reduction of onset of immunity of an active substance.
17 February 2010	Addition of suppliers of starting materials.
15 July 2009	Changes to Section 4.2 of the SPC.
24 May 2006	Changes to the SPC and product literature to bring them into line with new legislation.
24 May 2006	Change of legal category from POM to POM-V.

